Form 4: Ultragenyx CBO & EVP Thomas Kassberg Sells Shares
SEC Form 4 Filing
Ultragenyx Pharmaceutical's CBO & EVP, Thomas Richard Kassberg, sold 11,509 shares of common stock on March 11, 2024.
Summary
- On March 11, 2024, Thomas Richard Kassberg, the CBO & EVP of Ultragenyx Pharmaceutical Inc., sold 11,509 shares of the company's common stock.
- The shares were sold at a weighted average price of $49.93, with individual transactions ranging from $49.92 to $50.06.
- Following the transaction, Kassberg directly owns 252,823 shares, which includes shares underlying RSUs subject to vesting conditions.
Sentiment
Score: 5
Explanation: Neutral sentiment as it's a standard disclosure of stock sale by an executive. It doesn't inherently indicate positive or negative outlook for the company.
Industry Context
This is a routine disclosure of insider trading activity. It's common for executives to periodically sell shares for personal financial management.
Stakeholder Impact
- The sale of shares by an executive could have a minor psychological impact on shareholders, but is unlikely to have a significant material impact.
Key Dates
| Date | Description |
|---|---|
| 03/11/2024 | Date of stock sale transaction |
| 03/12/2024 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.